REVAMP: Management Guided by Genotypic Resistance Testing Following First-line ART Failure Comparable to Viral Load–Guided Management in Sub-Saharan Africa

Drs Monica Gandhi and Joseph Eron discuss next-line ART options for a heavily treatment-experienced patient with multiclass resistance .

Joseph J. Eron, Jr., MD Monica Gandhi, MD, MPH Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Pharmacists: 0.5 contact hours (0.05 CEUs) Released: April 19, 2021 Expired: April 18, 2022

Download CCO slides reviewing data and guidelines on next-line ART for heavily-treatment experienced patients with HIV and multiclass drug resistance

Joseph J. Eron, Jr., MD Monica Gandhi, MD, MPH Released: April 19, 2021

Expert commentary from CCO detailing the use of HIV-ASSIST to support ART selection in a socially- and medically-complex, treatment-experienced patient with HIV

Matthew M. Hamill, MBChB, MPH, MSc, PhD Released: April 9, 2021

由专家选择的 2021 年 CROI 中的重要 HIV 数据，包括当前和研究性的 ART 疗法以及孕期和产后的 ART 疗法。数据由 CCO 提供

Princy N. Kumar, MD, FIDSA, MACP Daniel R. Kuritzkes, MD Chloe Orkin, MBChB, FRCP, MD Released: April 9, 2021